[Lani]

Trish--this work was done in mice--it is certainly NOT standard of care and it may not yet be approved in Australia for use against established bone mets or osteoporosis (as it recently was in the US--former within past 4 months or some, the latter within the last year or so)

There are a few papers just being published on how to decide whether ZA or denosumab for any given patient--denosumab is much easier on the kidney for those with kidney insufficiency...but denosumab being a monoclonal antibody vs a simple nonbiologic chemical (ZA) is probably MUCH MORE EXPENSIVE

Most papers have felt denosumab is at least as good if not better and of course it is safer in those with kidney problems, but this is still in evolving field.

Hope this helps!